Table 1.
Patient characteristics by cohort and overall
| Evofosfamide Dose (mg/m2) | |||||
|---|---|---|---|---|---|
| 240 | 340 | 480 | 670 | Total | |
| (n = 3) | (n = 3) | (n = 4) | (n = 13) | (n = 23) | |
| Age, median (range) | 56 | 47 | 50 | 61 | 56 |
| (43–70) | (44–51) | (35–58) | (42–74) | (35–74) | |
| Male, n | 2 (67%) | 1 (33%) | 1 (25%) | 10 (77%) | 14 (61%) |
| ECOG status | |||||
| 0 | 0 | 0 | 1 (25%) | 3 (23%) | 4 (17%) |
| 1 | 3 (100%) | 3 (100%) | 3 (75%) | 7 (54%) | 16 (70%) |
| 2 | 0 | 0 | 0 | 3 (23%) | 3 (13%) |
| Prior therapies, median | 2 | 3 | 3 | 2 | 3 |
|
Months to progression on
chemo/radiation, median (range) |
11.3 | 9 | 15.6 | 4.5 | 6.6 |
| (2.7–14) | (7.8–14) | (4.5–20) | (1.8–14) | (1.8–20) | |
|
Months to progression on prior
Bev, median (range) |
3.5 | 1.4 | 2.3 | 4.1 | 3.7 |
| (2.5–6.5) | (1.1–4.9) | (1.3–5.5) | (1.0–9.0) | (1.0–9.0) | |
| Median months from progression on Bev to first dose Evo | 1.2 | 3.3 | 1.2 | 0.6 | 0.8 |
| Steroids at study entry | 1 (33%) | 2 (67%) | 0 (0%) | 9 (69%) | 12 (52%) |